AroCell AB (ST:AROC) — Market Cap & Net Worth
Market Cap & Net Worth: AroCell AB (AROC)
AroCell AB (ST:AROC) has a market capitalization of $13.39 Million (Skr124.39 Million) as of June 17, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #26332 globally and #560 in its home market, demonstrating a 4.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AroCell AB's stock price Skr0.54 by its total outstanding shares 230360992 (230.36 Million). Review how much debt does AroCell AB carry to assess the company's total debt and financial obligations.
AroCell AB Market Cap History: 2015 to 2025
AroCell AB's market capitalization history from 2015 to 2025. Data shows change from $270.22 Million to $13.39 Million (-28.65% CAGR).
Index Memberships
AroCell AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$16.06 Billion | 0.08% | #143 of 281 |
Weight: AroCell AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
AroCell AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AroCell AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.17x
AroCell AB's market cap is 0.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $270.22 Million | $460.22K | -$7.48 Million | 587.15x | N/A |
| 2016 | $173.52 Million | $54.61K | -$9.23 Million | 3177.70x | N/A |
| 2017 | $94.58 Million | $502.03K | -$17.27 Million | 188.40x | N/A |
| 2018 | $56.46 Million | $781.84K | -$20.76 Million | 72.21x | N/A |
| 2019 | $29.62 Million | $442.70K | -$16.20 Million | 66.92x | N/A |
| 2020 | $58.01 Million | $84.00K | -$19.46 Million | 690.59x | N/A |
| 2021 | $23.55 Million | $12.00 Million | -$50.03 Million | 1.96x | N/A |
| 2022 | $15.37 Million | $36.99 Million | -$58.97 Million | 0.42x | N/A |
| 2023 | $10.83 Million | $43.04 Million | -$59.30 Million | 0.25x | N/A |
| 2024 | $9.67 Million | $57.44 Million | -$42.45 Million | 0.17x | N/A |
Competitor Companies of AROC by Market Capitalization
Companies near AroCell AB in the global market cap rankings as of June 17, 2026.
Key companies related to AroCell AB by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #127 globally with a market cap of $177.57 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #182 globally with a market cap of $128.10 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #626 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #663 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #127 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.57 Billion | $472.63 |
| #182 | Danaher Corporation | NYSE:DHR | $128.10 Billion | $181.35 |
| #626 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $573.00 |
| #663 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
AroCell AB Historical Marketcap From 2015 to 2025
Between 2015 and today, AroCell AB's market cap moved from $270.22 Million to $ 13.39 Million, with a yearly change of -28.65%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Skr13.39 Million | +38.46% |
| 2024 | Skr9.67 Million | -10.76% |
| 2023 | Skr10.83 Million | -29.52% |
| 2022 | Skr15.37 Million | -34.74% |
| 2021 | Skr23.55 Million | -59.40% |
| 2020 | Skr58.01 Million | +95.82% |
| 2019 | Skr29.62 Million | -47.53% |
| 2018 | Skr56.46 Million | -40.31% |
| 2017 | Skr94.58 Million | -45.49% |
| 2016 | Skr173.52 Million | -35.78% |
| 2015 | Skr270.22 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of AroCell AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.39 Million USD |
| MoneyControl | $13.39 Million USD |
| MarketWatch | $13.39 Million USD |
| marketcap.company | $13.39 Million USD |
| Reuters | $13.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AroCell AB
AroCell AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cell; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. The company was formerly known as Xi Bao Research AB… Read more